文献速递消化道肿瘤放疗

直肠癌术前放化疗后最佳手术间隔:7项随机试验3085例汇总分析

Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials.
PubMed 文献 · Radiother Oncol · 2020-09-20

该汇总分析纳入7项国际随机试验共3085例局部晚期直肠癌患者,评估术前放化疗后手术间隔对病理完全缓解率(pCR)及生存结局的影响。结果显示总体pCR率为14%,中位手术间隔6周(范围1–31周),延长手术间隔、放疗剂量及联合奥沙利铂均有利于提高pCR,且延长间隔未影响局部复发、远处转移和总生存。

要点

  • 总体pCR率14%,中位手术间隔6周(范围1–31周)。
  • 延长手术间隔、放疗剂量及联合奥沙利铂均显著有利于pCR。
  • 延长手术间隔未影响局部复发、远处转移和总生存。

核心结论

  • 局部晚期直肠癌术前放化疗后,达到最高pCR率的最佳手术时间为10周,且延长手术间隔对生存结局无不利影响。

研究设计与样本

  • 汇总分析7项国际随机试验(Accord12/0405、EORTC22921、FFCD9203、CAO/ARO/AIO-94、CAO-ARO-AIO-04、INTERACT、TROG01.04)共3085例患者。
  • 纳入标准为年龄≥18岁、cT3-T4和cN0-2、诊断时无远处转移临床证据、接受术前放化疗后手术。

主要发现

  • 总体pCR率为14%,中位手术间隔6周(范围1–31周)。
  • 随手术间隔延长,累积pCR率显著增加,95%的pCR事件发生在术前放化疗后10周内。
  • 单因素和多因素logistic回归分析显示,延长手术间隔(p<0.01)、放疗剂量(p<0.01)及术前放化疗联合奥沙利铂(p<0.01)均对pCR有有利影响。
  • 延长手术间隔未影响局部复发、远处转移和总生存。

关键数值与推荐

  • 达到最高pCR率的最佳手术时间为10周。
  • 延长手术间隔对生存结局无不利影响。

临床怎么用

  • 对于局部晚期直肠癌术前放化疗后患者,可考虑将手术间隔延长至约10周以提高pCR率,且不增加生存风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Optimal timing of surgery after neoadjuvant chemoradiotherapy (Nad-CRT) is still controversial in locally advanced rectal cancer (LARC). The primary goal of this study was to determine the best surgical interval (SI) to achieve the highest rate of pathological complete response (pCR) and secondly to evaluate the effect on survival outcomes according to the SI. PATIENTS AND METHODS: Patients data were extracted from the international randomized trials: Accord12/0405, EORTC22921, FFCD9203, CAO/ARO/AIO-94, CAO-ARO-AIO-04, INTERACT and TROG01.04. Inclusion criteria were: age≥ 18, cT3-T4 and cN0-2, no clinical evidence of distant metastasis at diagnosis, Nad-CRT followed by surgery. Pearson's Chi-squared test with Yates' continuity correction for categorical variables, the Mann-Whitney test for continuous variables, Mann-Kendall test, Kaplan-Meier curves with log-rank test, univariate and multivariate logistic regression model was used for data analysis. RESULTS: 3085 patients met the inclusion criteria. Overall, the pCR rate was 14% at a median SI of 6 weeks (range 1-31). The cumulative pCR rate increased significantly when SI lengthened, with 95% of pCR events within 10 weeks from Nad-CRT. At univariate and multivariate logistic regression analysis, lengthening of SI (p< 0.01), radiotherapy dose (p< 0.01), and the addition of oxaliplatin to Nad-CRT (p< 0.01) had a favorable impact on pCR. Furthermore, lengthening of SI was not impact on local recurrences, distance metastases, and overall survival. CONCLUSION: This pooled analysis suggests that the best time to achieve pCR in LARC is at 10 weeks, considering that the lengthening of SI is not detrimental concerning survival outcomes.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Gambacorta MA, Masciocchi C, Chiloiro G, et al. Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials. Radiother Oncol. 2020. PMID: 32966845. doi:10.1016/j.radonc.2020.09.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。